Immuneed - Immunotherapy Unit's Unit Acquisition

Immuneed - Immunotherapy Unit raised a round of funding on August 30, 2018. Investors include Ultimovacs.

Immueed specializes in advanced ex vivo characterization of biotherapeutics to provide a better understanding of first-in-man reactions prior to clinical trial entry.…

Articles about Immuneed - Immunotherapy Unit's Unit Acquisition: